0A8K Stock Overview
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ImmunoGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.24 |
| 52 Week High | US$31.25 |
| 52 Week Low | US$3.66 |
| Beta | 1.17 |
| 1 Month Change | 4.80% |
| 3 Month Change | 97.21% |
| 1 Year Change | 658.25% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 307.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A8K | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 6.4% | 2.1% | 1.4% |
| 1Y | 658.3% | -27.7% | 1.1% |
Return vs Industry: 0A8K exceeded the UK Biotechs industry which returned -23.8% over the past year.
Return vs Market: 0A8K exceeded the UK Market which returned -5.7% over the past year.
Price Volatility
| 0A8K volatility | |
|---|---|
| 0A8K Average Weekly Movement | 23.7% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A8K's share price has been volatile over the past 3 months.
Volatility Over Time: 0A8K's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 277 | Mark Enyedy | www.immunogen.com |
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate.
ImmunoGen, Inc. Fundamentals Summary
| 0A8K fundamental statistics | |
|---|---|
| Market cap | US$8.36b |
| Earnings (TTM) | -US$73.52m |
| Revenue (TTM) | US$287.61m |
29.1x
P/S Ratio-113.7x
P/E RatioIs 0A8K overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A8K income statement (TTM) | |
|---|---|
| Revenue | US$287.61m |
| Cost of Revenue | US$211.62m |
| Gross Profit | US$76.00m |
| Other Expenses | US$149.52m |
| Earnings | -US$73.52m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 26.42% |
| Net Profit Margin | -25.56% |
| Debt/Equity Ratio | 12.8% |
How did 0A8K perform over the long term?
See historical performance and comparison